Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Adicon Holdings's ROE % or its related term are showing as below:
HKSE:09860'
s ROE % Range Over the Past 10 Years
Min: 1.1 Med: 24.41 Max: 97.77
Current: 1.1
During the past 6 years, Adicon Holdings's highest ROE % was 97.77%. The lowest was 1.10%. And the median was 24.41%.
HKSE:09860's ROE % is ranked better than 57% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.29
vs HKSE:09860: 1.10
Adicon Holdings (HKSE:09860) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Adicon Holdings ROE % Related Terms
Adicon Holdings ROE % Historical Data
* Premium members only.
The historical data trend for Adicon Holdings's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Adicon Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicon Holdings ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adicon Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Adicon Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Adicon Holdings (HKSE:09860) has a ROE % of -1.06% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Adicon Holdings and its competitors. Over the past decade, Adicon Holdings' ROE % has ranged from 1.10 to 97.77. According to the industry distribution chart, Adicon Holdings ranks #86 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 43%.
Is Adicon Holdings' ROE % too high?
Adicon Holdings' current ROE % is -1.06%. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 97.77. Based on the distribution chart, Adicon Holdings ranks #86 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Adicon Holdings has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adicon Holdings' ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Adicon Holdings ranks #86 out of 200 companies for ROE %. This puts Adicon Holdings in the upper half of its industry. Historically, Adicon Holdings' own ROE % has ranged from 1.10 to 97.77 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Adicon Holdings and its competitors. Adicon Holdings's current ROE % is -1.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicon Holdings stock overvalued right now?
Based on GuruFocus' analysis, Adicon Holdings (HKSE:09860) is currently considered Possible Value Trap. The stock's GF Value™ is HK$7.19, compared to a current price of HK$3.33 — trading 53.7% below its estimated fair value. The current ROE % is -1.06%. Adicon Holdings' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Adicon Holdings (HKSE:09860), the current ROE % is -1.06% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicon Holdings (HKSE:09860) Overvalued in 2026?
Based on GuruFocus' analysis, Adicon Holdings stock appears to be undervalued.
The current stock price of HK$3.33 is trading 53.7% below its estimated GF Value™ of HK$7.19.
GuruFocus considers Adicon Holdings to be Possible Value Trap.
Key valuation signals for HKSE:09860:
ROE %: -1.06%
GF Value™: HK$7.19 vs. price of HK$3.33 (53.7% below fair value)
No single metric tells the full story. See the HKSE:09860 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicon Holdings Ltd is a ICL service provider in China. It offers comprehensive testing services to hospitals and health check centers through an integrated network of self-operated laboratories across China. Its testing services platform includes clinical laboratories, pathology laboratories, reproductive genetics laboratories, gene laboratories, and mass spectrometry laboratories, consisting of over 4,000 medical diagnostic tests, the introduction of over 300 new high-end diagnostic tests.
75GF Score
Get the complete analysis for HKSE:09860
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09860 has been successfully added to your 
